

ABSTRACT

The present disclosure relates to novel heterotricyclic derivative compounds and the use thereof, and more particularly, to novel heterotricyclic derivative compounds having inhibitory activity against EZH1 (enhancer of zeste homolog 1) and/or EZH2
5 (enhancer of zeste homolog 2) activity, pharmaceutically acceptable salts thereof, or pharmaceutical compositions containing these compounds.